Related Experiment Video
Updated: Jun 27, 2026
Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
Published on: December 12, 2025
Mesenchymal stem cell-derived microvesicles confer protection against rheumatoid arthritis-associated interstitial
Xiuping Liang1, Yanhong Li1, Ziyi Tang1
1Department of Rheumatology & Immunology, Laboratory of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Background:
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a serious condition with few treatment options and a poor outlook. Mesenchymal stem cell-derived microvesicles (MSC-MVs) offer a potential cell-free therapy, but their effectiveness and the role of their miRNA content in RA-ILD are not well understood.
Methods:
A mouse model of comorbid RA-ILD was created using collagen-induced arthritis and bleomycin-induced pulmonary fibrosis. Mice received high- or low-dose MSC-MVs via tail vein injection. The treatment effectiveness was evaluated by assessing arthritis severity and pulmonary fibrosis through clinical scores, imaging, histopathology, lung function, and lung coefficients. The expression of fibrotic markers in the lungs was measured using immunohistochemistry and Western blotting. Small RNA sequencing of MSCs-MVs was conducted to explore the underlying mechanism.
Results:
Administering MSCs-MVs significantly reduced the severity of arthritis and pulmonary fibrosis. Treated mice had better joint and lung scores, with decreased fibrotic areas and lower levels of fibrotic proteins such as anti-α-smooth muscle actin, collagen I, and fibronectin. Small RNA sequencing revealed that MSC-MVs contain microRNAs (miRNAs) (e.g., miR-148a-3p) that target critical pathways in RA-ILD, such as transforming growth factor-β (TGF-β) and Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling.
Conclusions:
Our research revealed that MSCs-MVs significantly protect against RA-ILD in a comorbid model. This protective effect is likely facilitated by the transfer of specific miRNAs that modulate essential profibrotic and inflammatory pathways. These results underscore the therapeutic potential of MSC-MVs as an innovative cell-free approach for RA-ILD treatment and identify miRNA-mediated pathway regulation as a pivotal mechanism.
Insights
Mesenchymal stem cell-derived microvesicles (MSC-MVs) show promise in treating rheumatoid arthritis-associated interstitial lung disease (RA-ILD). These microvesicles reduce arthritis and lung fibrosis by transferring microRNAs that target key inflammatory pathways.
Area of Science:
- Regenerative Medicine
- Immunology
- Pulmonology
Background:
- Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) presents a significant clinical challenge with limited therapeutic options.
- Mesenchymal stem cell-derived microvesicles (MSC-MVs) are being explored as a cell-free therapeutic strategy for RA-ILD.
- The precise mechanisms and efficacy of MSC-MVs, particularly their miRNA cargo, in treating RA-ILD remain incompletely understood.
Purpose of the Study:
- To investigate the therapeutic potential of MSC-MVs in a preclinical model of comorbid rheumatoid arthritis and interstitial lung disease (RA-ILD).
- To elucidate the underlying mechanisms of MSC-MV action, focusing on the role of microRNA (miRNA) content.
Main Methods:
- A comorbid mouse model of RA-ILD was established using collagen-induced arthritis and bleomycin-induced pulmonary fibrosis.
- Mice were treated with varying doses of MSC-MVs administered intravenously.
- Therapeutic efficacy was assessed through clinical scoring, imaging, histopathology, lung function tests, and molecular analysis of fibrotic markers and miRNA profiles.
Main Results:
- MSC-MV treatment significantly ameliorated both arthritis severity and pulmonary fibrosis in the RA-ILD model.
- Histopathological and molecular analyses revealed reduced fibrotic markers (e.g., α-SMA, collagen I) and improved lung architecture in treated mice.
- Small RNA sequencing identified specific miRNAs within MSC-MVs, such as miR-148a-3p, capable of targeting profibrotic and inflammatory signaling pathways (e.g., TGF-β, JAK-STAT).
Conclusions:
- MSCs-MVs demonstrate significant protective effects against RA-ILD in a comorbid preclinical model.
- The therapeutic benefits are attributed to the transfer of specific miRNAs that modulate key profibrotic and inflammatory pathways.
- These findings highlight MSC-MVs as a promising cell-free therapeutic agent for RA-ILD, with miRNA-mediated pathway modulation being a critical mechanism.
Related Concept Videos
01:19Mesenchymal Stem Cells
01:29Respiratory Syncytial Virus Disease